Renal dysfunction following autologous bone marrow transplantation in adult patients with acute leukemia

被引:8
作者
Glynne, P [1 ]
Powles, R [1 ]
Steele, J [1 ]
Singhal, S [1 ]
Treleaven, J [1 ]
Tait, D [1 ]
Mehta, J [1 ]
机构
[1] ROYAL MARSDEN HOSP,LEUKAEMIA UNIT,SUTTON SM2 5PT,SURREY,ENGLAND
关键词
D O I
10.3109/02841869609084003
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The serum creatinine level was used to determine the incidence of renal dysfunction in 70 adults with acute leukemia who were alive and well one year following autologous bone marrow transplantation (ABMT), Creatinine measurements at the time of ABMT, one year post-ABMT and at the last follow-up (12-128 months, median 35) were recorded, and a level of >120 mu mol/l arbitrarily defined as clinically significant renal impairment, The incidence of renal impairment was 2.9% (n = 2) at 1 year, and 4.3% (n = 3) at the last follow-up in continuous remission, Significant renal impairment occurred after relapse in 8 of 12 patients, but was seen in only 3 of 58 patients who remained in remission (p < 0.001, Fisher's exact test), suggesting subclinical renal damage which became obvious with further nephrotoxic therapy. We conclude that clinically significant renal dysfunction is an uncommon long-term complication of ABMT, and should not be a concern in recommending this therapy to eligible patients.
引用
收藏
页码:709 / 712
页数:4
相关论文
共 18 条
[1]   DELAYED RENAL-FAILURE WITH EXTENSIVE MESANGIOLYSIS FOLLOWING BONE-MARROW TRANSPLANTATION [J].
ANTIGNAC, C ;
GUBLER, MC ;
LEVERGER, G ;
BROYER, M ;
HABIB, R ;
LACOSTE, M ;
BEZIAU, A ;
NAIZOT, C .
KIDNEY INTERNATIONAL, 1989, 35 (06) :1336-1344
[2]   REGIMEN-RELATED TOXICITY AND EARLY POSTTRANSPLANT SURVIVAL IN PATIENTS UNDERGOING MARROW TRANSPLANTATION FOR LYMPHOMA [J].
BEARMAN, SI ;
APPELBAUM, FR ;
BACK, A ;
PETERSEN, FB ;
BUCKNER, CD ;
SULLIVAN, KM ;
SCHOCH, HG ;
FISHER, LD ;
THOMAS, ED .
JOURNAL OF CLINICAL ONCOLOGY, 1989, 7 (09) :1288-1294
[3]  
DEEG HJ, 1990, HEMATOL ONCOL CLIN N, V4, P641
[4]   CHRONIC CYCLOSPORINE-ASSOCIATED NEPHROTOXICITY IN BONE-MARROW TRANSPLANT PATIENTS [J].
DIETERLE, A ;
GRATWOHL, A ;
NIZZE, H ;
HUSER, B ;
MIHATSCH, MJ ;
THIEL, G ;
TICHELLI, A ;
SIGNER, E ;
NISSEN, C ;
SPECK, B .
TRANSPLANTATION, 1990, 49 (06) :1093-1100
[5]   CORRELATION OF SERUM CYCLOSPORINE CONCENTRATION WITH RENAL DYSFUNCTION IN MARROW TRANSPLANT RECIPIENTS [J].
KENNEDY, MS ;
YEE, GC ;
MCGUIRE, TR ;
LEONARD, TM ;
CROWLEY, JJ ;
DEEG, HJ .
TRANSPLANTATION, 1985, 40 (03) :249-253
[6]  
KONE BC, 1988, Q J MED, V69, P985
[7]  
LAWTON CA, 1991, CANCER-AM CANCER SOC, V67, P2795, DOI 10.1002/1097-0142(19910601)67:11<2795::AID-CNCR2820671114>3.0.CO
[8]  
2-D
[9]   THE ROLE OF CYCLOSPORINE DOSAGE AND PLASMA-LEVELS IN EFFICACY AND TOXICITY IN BONE-MARROW TRANSPLANT RECIPIENTS [J].
LINDHOLM, A ;
RINGDEN, O ;
LONNQVIST, B .
TRANSPLANTATION, 1987, 43 (05) :680-684
[10]  
LONNERHOLM G, 1991, BONE MARROW TRANSPL, V8, P129